Salute e Benessere

Pharmaceutical Suspension Market to Reach $83.8 Billion, Globally, by 2032 at…

Sample of the Report on Pharmaceutical Suspension Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/A12351 Sample of the Report on Pharmaceutical Suspension Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/A12351 Prime determinants of growth Growing healthcare infrastructure, rise in prevalence of disease conditions that require effective treatment, and growing awareness regarding the use of pharmaceutical suspension are factors that...
PR Newswire
14/02/2024

Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences…

Investors have committed to participate in the transaction in the form of $20 million in convertible debt (which includes bridge financing for the period between signing and closing) and $22 million in equity financing (which includes the non-redemption of cash in ARYA's trust account). Investors in the financing include affiliates of Perceptive Advisors, RA Capital Management ("RA Capital"), RTW Investments and ATW Partners. Investors have committed to participate in the transaction…
PR Newswire
14/02/2024

Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with…

SEOUL, South Korea,Feb. 14, 2024/PRNewswire/ -- CART BP is a ring-type 24/7 blood pressure monitor of the global healthcare startupSky Labs (CEO Jack, Lee), and has fully established itself as the only ring-type wearable medical device to complete comparative studies with all blood pressure measurement methods, becoming the first in the world. There are currently three main blood pressure measurement methods: auscultatory method in which a cuff-based blood pressure monitor...
PR Newswire
14/02/2024

Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration…

NM49 is a multi-specific antibody identified through Numab's proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosisNumab to receive upfront payment and eligible to receive additional milestone payments plus option to co-develop with profit split arrangement in the United StatesAgreement marks third collaboration agreement between Numab and Ono Pharmaceutical HORGEN, Switzerland, Feb.14, 2024(GLOBE NEWSWIRE) -- ...
Nasdaq GlobeNewswire
14/02/2024

Hundreds of sickle cell patients to benefit from £1.5M technology investment

There are approximately 15,000 people in the England with sickle cell disease, and around 10% of these are eligible for the treatment on the NHS. Investment in the rollout of this technology could provide an additional 10,000 apheresis procedures annually. There are approximately 15,000 people in theEnglandwith sickle cell disease, and around 10% of these are eligible for the treatment on the NHS. Investment in the rollout of this technology could provide an additional 10,000 apheresis...
PR Newswire
14/02/2024

Beactica Therapeutics' TEAD programme selected for late-breaking research…

The presentation will include new positive results from studies with novel proteolysis-targeting degraders of TEAD based on interface 3-binding ligands under development by Beactica. This will include head-to-head in vitro comparisons with other classes of TEAD modulators in clinical development such as palmitoylation inhibitors and direct YAP–TEAD protein–protein interaction inhibitors. The work to be presented contains contributions by Beactica's collaborators at the National Center for…
PR Newswire
14/02/2024

Mendus AB Year-end Report for 2023

Press Release Stockholm, Sweden, February 14, 2024Positive ADVANCE II data at ASH caps strong 2023The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen the development of our lead product vididencel as a novel maintenance treatment for acute myeloid leukemia (AML). Mendus is at an exciting point in its journey, supported by continued positive clinical data confirming the potential of vididencel to significantly...
Nasdaq GlobeNewswire
14/02/2024

Invitation to the presentation of Calliditas´ Year-end report January - December…

The presentation will be given in English. The presentation will be given in English. Link to the webcast:https://ir.financialhearings.com/calliditas-therapeutics-q4-report-2023 To participate via conference call please register via this link:https://conference.financialhearings.com/teleconference/?id=50046870 After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity...
PR Newswire
14/02/2024

High Perfumery House Amouage opens first standalone flagship in the Americas

A treasured moment. A treasured moment. The initiatory journey to the heart of Amouage begins right from the store's façade, with its colored veils pierced by concentric arches, which punctuate the perspective and recreate the unique cameo of the Omani valleys. Each veil evokes a moment in the sunset, delimiting a space and defining a function in the path of discovery. The rocky lacework on the right-hand side surrounds a monumental screen, which will present a seasonal digital art...
PR Newswire
14/02/2024

Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides…

Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs' lead indication, advanced malignant melanoma Topline result will report primary endpoint of progression-free survival (PFS) of UV1 vaccination combined with standard of care immunotherapy over immunotherapy alonePositive results from the INITIUM trial will be further presented at an international medical conference and published in a reputable medical journal UV1 granted Fast Track...
Nasdaq GlobeNewswire
14/02/2024

PCI Biotech second half 2023 interim results

Highlights review OperationsThe use offima NAc in gene therapy manufacturing has since its inception in 2022 generated results supporting the notion of applying photochemical methods to increase yield and reduce impurities in bioprocessing, specifically viral vector manufacturing.The most recently reported 2023 milestone was initiation of field testing in Q4 with an international life science group that provides a range of products and services to the biopharmaceutical...
Nasdaq GlobeNewswire
14/02/2024

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with…

Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE® has shown safety benefits in patients switching from standard of care corticosteroids in terms of recovery of bone health and growth More than 200 patients have now been treated with vamorolone for up to 84 months across clinical studies and access programs AGAMREE® is the only approved medication in...
Nasdaq GlobeNewswire
14/02/2024

Voting Rights and Shares Capital of the Company

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Feb.13, 2024(GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
13/02/2024

Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in…

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde ®regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus nab-paclitaxel and gemcitabine1NAPOLI 3 represents the first positive Phase III trial in first-line metastatic pancreatic adenocarcinoma (mPDAC) to demonstrate superior overall survival versus the currently approved regimen of nab-paclitaxel and...
Nasdaq GlobeNewswire
13/02/2024

CRISPR Market to Explode: $3.4 Billion Today, $17.8 Billion by 2034, Fueled by…

Request Exclusive Sample Report: CRISPR Industry Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-18982 Request Exclusive Sample Report: CRISPR Industry Strategic Insights,https://www.futuremarketinsights.com/reports/sample/rep-gb-18982 The increasing funding and assistance from governments, individual investors, and venture capital companies is an essential component propelling the CRISPR market. This funding supports research and development as...
PR Newswire
13/02/2024

The Curtain Wall Market to Worth $165.76 Billion by 2029, Boom in Modern…

Browse In-depth TOC on the Curtain Wall Market Browse In-depth TOC on the Curtain Wall Market 300 – Pages 95 - Tables 72 - Figures The global curtain wall market has undergone significant transformation due to technological advancements, emphasizing energy efficiency, smart building solutions, and sustainable materials. Curtain wall systems, which are non-structural exterior facades made of lightweight materials like aluminum and glass, have evolved to...
PR Newswire
13/02/2024

The Ventilators Market to Hit $2.56 Billion by 2029, Tremendous Growth…

Ventilators are vital to healthcare services, from hospitals to ambulatory healthcare services and homecare settings. The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth. Ventilators are vital to healthcare services, from hospitals to ambulatory healthcare services and homecare settings. The changing healthcare services in emerging markets and significant achieved development with...
PR Newswire
13/02/2024

Calliditas provides patent update

Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China. Calliditas intends to file corresponding patent applications in additional territories around the world, includingEuropeandChina. "We are delighted with the additional product protection and longer runway until patent expiration with regards to TARPEYO and look forward to successful processes also in other geographies", said CEO Renée Aguiar-Lucander...
PR Newswire
13/02/2024

Medical Nitrous Oxide Market Worth $2.8 Billion | MarketsandMarkets™

Browse in-depth TOC on "Medical Nitrous Oxide Market" Browse in-depth TOC on "Medical Nitrous Oxide Market" 110 - Tables 55 - Figures 220 - Pages Medical Nitrous Oxide Market Scope: The gaseous state segment is expected to register the highest growth of the medical nitrous oxide market By product, the global medical nitrous oxide market is categorized into liquid state and gaseous state. The gaseous segment is expected to register the highest growth of the medical...
PR Newswire
13/02/2024

Global Healthcare E-commerce Market to Accrue $1038.17 Billion by 2030…

E-commerce platforms offer medical professionals and institutions access to an extensive array of medical equipment, ranging from diagnostic tools to surgical instruments. Healthcare e-commerce seamlessly incorporates telehealth and telemedicine services, facilitating remote consultations between patients and healthcare providers, including the online issuance of prescriptions. E-commerce platforms offer medical professionals and institutions access to an extensive array of medical equipment,...
PR Newswire
13/02/2024

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces…

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of blood.Cyclomics' 4th generation liquid biopsy genomics platform is a truly “Omni-Omic” blood test ready for AI applicationGEDiCube's award-winning AI is developing high-performance biomarker panels for 13 different cancers. GEDiCube's partnership with NVIDIA's...
Nasdaq GlobeNewswire
13/02/2024

AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces…

The combination will see Renovaro's existing CEO, The Hon. Mark Dybul, MD, leading Renovaro Inc., with GEDiCube's CEO, Coen van Kalken, MD PhD, becoming the Managing Director and President of GEDiCube and Dr. Francois Binette, currently, Executive Vice-President and COO of Renovaro, becoming the Managing Director and President of Renovaro Biosciences.“We believe this combination marks a significant milestone in the journey of personalized medicine,” said Dr. Dybul. “Together, we believe...
Nasdaq GlobeNewswire
13/02/2024

Global Skin Lightening Products Market to Accrue $14.57 Billion by 2030, Driven…

Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/skin-lightening-products-market-362 Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/skin-lightening-products-market-362 Trending Now: Univar Solutions and ImDerma Laboratories Forge Exclusive Partnership InDecember 2023, Univar Solutions Inc., a prominent global solutions provider specializing in specialty ingredients and chemicals, inked an exclusive distribution agreement...
PR Newswire
13/02/2024

Commercial Kitchen Appliances Market to Hit USD 149.70 Billion by 2030, Growing…

Commercial kitchen appliances are generally larger and more robust compared to residential ones, enabling chefs and kitchen personnel to efficiently handle large quantities of food. Furthermore, these appliances often incorporate advanced functionalities like temperature regulation, multiple cooking zones, and specialized features tailored to meet the distinct requirements of professional chefs and culinary establishments. Commercial kitchen appliances are generally larger and more robust...
PR Newswire
13/02/2024
Altri  Comunicati